Table 1.
Demographic, treatment, and lesion characteristics at time of oligometastasis
| Oligometastatic characteristics | N = 131 | Treated lesion characteristics | N = 261 |
|---|---|---|---|
| Median age at oligomet (IQR) | 66 (60.75-66) | Location | |
| Median PSA at oligomet (IQR) | 4.5(1.9-11.8) | Node | 118 (45.2%) |
| Bone | 137 (52.5%) | ||
| Visceral | 3 (1.1%) | ||
| Prostate/Local recurrence | 1 (0.4%) | ||
| Timing | |||
| Metachronous | 97 (74.0%) | ||
| Synchronous/de novo | 34 (25.2%) | Median pre-MDT SUVmax (IQR) | |
| All Lesions | 8.7 (4.0-16.7) | ||
| Staging imaging | Node | 9.1(4.0-18.5) | |
| Conventional (CT/Bone Scan) | 35 (26.7%) | Bone | 8.6 (4.2-15.7) |
| PSMA-PET | 96 (73.3%) | Visceral | 7.8 (6.2-10.2) |
| Number of PSMA lesions | Median BED3 Gy (IQR) | ||
| 1 | 62 (47.3%) | All Lesions | 116.7(90-126) |
| 2 | 42 (32.1%) | Node | 116.7 (90-124) |
| 3 | 12 (9.2%) | Bone | 116.7 (90-126) |
| ≥ 4 | 15 (11.5%) | Visceral | 378 (234-419) |
| Total PSMA consolidation | PSMA SUV response | ||
| Yes | 115 (87.8%) | Complete response | 72 (27.6%) |
| No | 16 (12.2%) | Partial response | 135 (51.7%) |
| ADT with MDT | Stable disease | 37 (14.2%) | |
| Yes | 86 (65.6%) | Progressive disease | 17 (6.5%) |
| No | 45 (34.4%) | ||
| Median duration of ADT (IQR) | 2 (1.0-3.75) mo. | ||
| Mode of failure | |||
| Long-term disease free | 64 (48.9%) | ||
| Oligoprogressor | 32 (24.4%) | ||
| Polyprogressor | 35 (26.7%) |
Abbreviations: ADT = androgen deprivation therapy; MDT = metastasis-directed therapy; PSA = prostate-specific antigen; PSMA-PET = prostate-specific membrane antigen positron emissssion tomography; SUV = standardized uptake value.